We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GeneBio's Phenyx Chosen by British Columbia Proteomics Network

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GeneBio's Phenyx Chosen by British Columbia Proteomics Network"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Geneva Bioinformatics (GeneBio) SA and the BC Proteomics Network (BCPN) has announced an agreement that sees GeneBio’s Phenyx protein identification platform installed at the BCPN in order to facilitate MS/MS database search functionality for all BCPN members. Phenyx will be installed on the BCPN’s centralized server and will be available to all members of the BCPN network.

A profound analysis was conducted at the BCPN to understand which tools users needed on their network; the addition of Phenyx was amongst the top requirements. After conducting an intensive evaluation, the BCPN discovered in Phenyx a very dynamic and flexible tool generating excellent results.

The addition of Phenyx complements the existing search tools on the network and further solidifies Phenyx as a key element to any high throughput proteomics project that allows life scientists to produce identifications with a high degree of confidence.

Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data, specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment while offering a flexible user experience and an adaptable architecture to help instill confidence in results assessment.

“The use of Phenyx by the BCPN is a great win for us and in line with our goals,” said Nasri Nahas, CEO of GeneBio.

“Phenyx was designed for industrial use and massive scalability, and thus can accommodate both small and large cluster environments. Phenyx is already being utilized in numerous large-scale projects, like the HUPO Brain and Liver initiatives, amongst others; the addition of the BCPN is a testimony to the robustness and flexibility of this software. We look forward to our collaboration with the BCPN and to helping the BCPN improve and expand the reach of their formidable proteomics platform.”